Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8529 in Adult Schizophrenia
NCT00921804Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2009
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD8529 in schizophrenia (3 arms), sponsored by AstraZeneca. Primary endpoint: Positive and Negative Syndrome Scale Total Score at Day 28. Started Jun 2009; status: completed.
02
Drugs
AZD8529
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00921804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00921804.